Active, Not Recruiting
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05761951
- Conditions
- Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States